In order to quantify the efficacy of CK2 inhibition in primary CML cells, we obtained samples from two patients with CML who were unresponsive response to other TKIs (nilotinib and bosutinib), and who did not have mutations in the BCR-ABL kinase domain (patient characteristics are listed in Table 3). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.